Ono Pharmaceutical (OTCMKTS:OPHLY) Trading 1% Higher – Should You Buy?

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLYGet Free Report)’s stock price traded up 1% on Thursday . The company traded as high as $5.22 and last traded at $5.21. 8,164 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 19,819 shares. The stock had previously closed at $5.1565.

Ono Pharmaceutical Stock Performance

The stock’s 50-day simple moving average is $4.71 and its 200 day simple moving average is $4.19.

About Ono Pharmaceutical

(Get Free Report)

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.

Read More

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.